Otolaryngologic Side Effects of GLP ‐1 Receptor Agonists
The Laryngoscope · 2025-07 · 135 (7) · 2291-2298
DOI: 10.1002/lary.32061 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 12.02.2025. Verfasst von Faizaan I Khan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Texas A&M School of Engineering Medicine, Houston, Texas, U.S.A. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Otorhinolaryngologic Diseases. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Objectives
With the increasing use of GLP‐1 receptor agonist (GLP‐1 RA) drugs for weight loss and diabetes management, concerns have been raised regarding their potential side effects. We aim to assess the frequency of otolaryngologic adverse events (AEs). Study Design Retrospective analysis of national registry.
Methods
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP‐1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023. AEs were collected and sub‐stratified according to anatomic site. Reporting odds ratios (ROR) and proportional reporting ratios (PRR) were determined for all AEs.
Results
The number of AEs reported from all drugs within this study totaled 9,746. Significant signal ratios were defined as a PRR≥2 and a lower CI ROR >1. Medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) had the highest signals and were significant in virtually all medications. This was followed by GERD which also had very high signal ratios and was significant in all drugs assessed. Semaglutide also had significant signals in anosmia, dry mouth, dysgeusia, and Bell's palsy. Liraglutide had significance in both signals in dysphonia, dysgeusia, tinnitus, and Bell's palsy. This was followed by exenatide which also included dysgeusia and hearing disability.
Conclusions
GLP‐1 RA were associated with various otolaryngologic AEs, with significant signals observed for semaglutide and liraglutide. GERD, MTC, and PTC were of significance in all GLP‐1 RA in this study. Monitoring these AEs is recommended. Level of Evidence 4 Laryngoscope , 135:2291–2298, 2025
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Texas A&M School of Engineering Medicine, Houston, Texas, U.S.A.
- Department of Otolaryngology-Head and Neck Surgery, Houston Methodist Hospital, Houston, Texas, U.S.A.
ORCID-Profile: Faizaan I Khan, Zain Mehdi, Samuel Razmi, Keyvon Rashidi, Aatin Dhanda
Zitieren
APA
Khan, F. I., Vazquez, S. G., Mehdi, Z., Somawardana, I., Dongre, R., Razmi, S., Rashidi, K., Shenoi, J., Khan, N., Dhanda, A., Takashima, M., & Ahmed, O. G. (2025). Otolaryngologic Side Effects of GLP ‐1 Receptor Agonists. The Laryngoscope, 135(7), 2291-2298. https://doi.org/10.1002/lary.32061
Vancouver
Khan FI, Vazquez SG, Mehdi Z, Somawardana I, Dongre R, Razmi S, et al. Otolaryngologic Side Effects of GLP ‐1 Receptor Agonists. The Laryngoscope. 2025;135(7):2291-2298. doi:10.1002/lary.32061
BibTeX
@article{Khan2025,
author = {Khan, Faizaan I and Vazquez, Sebastian Guadarrama-Sistos and Mehdi, Zain and Somawardana, Isuru and Dongre, Roshan and Razmi, Samuel and Rashidi, Keyvon and Shenoi, Jason and Khan, Najm and Dhanda, Aatin and Takashima, Masayoshi and Ahmed, Omar G},
title = {Otolaryngologic Side Effects of GLP ‐1 Receptor Agonists},
journal = {The Laryngoscope},
year = {2025},
volume = {135},
number = {7},
pages = {2291--2298},
doi = {10.1002/lary.32061}
}
EUVIMED